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Background
HIV-infected individuals are at increased risk for primary
LC. We wished to compare the clinico-pathologic fea-
tures and treatment outcome of HIV-LC patients with
HIV-negative LC patients. We also sought to compare
smoking habits and immunologic features of HIV-LC
patients with HIV-positive patients without LC.
Methods
A database of 75 HIV-positive patients with primary LC
in the HAART era was established from an international
collaboration. These cases were drawn from the archives
of contributing physicians who subspecialize in HIV
malignancies. Patient characteristics were compared
with registry data from the Surveillance Epidemiology
and End Results (SEER, n=169,091 participants)
Program and with HIV-positive individuals without LC
from the Adult and Adolescent Spectrum of HIV-related
Diseases (ASD, n=36,569 participants) Project.
Results
The median age at HIV-related LC diagnosis was
50 years compared to 68 years for SEER participants
(p<0.001). HIV-LC patients, like their SEER counter-
parts, most frequently presented with stage III (29% vs.
32%) and stage IV (55% vs. 48%) cancers, usually with
adenocarcinoma (41% vs. 37%) or squamous carcinoma
(32% vs. 20%) histologies. HIV-LC patients and ASD
participants had comparable median nadir CD4+ cell
counts (138 vs. 160 cells/μL). HIV-LC patients were,
however, more likely to be smokers (99% vs. 76%;
p<0.001) with a higher median pack-year history of
cigarette consumption (41 vs. 14 pack-years; p<0.001).
At LC diagnosis, their median CD4+ count was
340 cells/μL and 86% were receiving HAART. Sixty-three
(84%) HIV-LC patients received cancer-specific treat-
ments, but chemotherapy-associated toxicity was sub-
stantial. The median survival among HIV-LC patients
and SEER participants both measured 9 months.
Conclusions
Smoking was tightly associated with the risk of HIV-LC.
Most HIV patients were receiving HAART and had sub-
stantial immune reconstitution at time of LC diagnosis.
They were able to receive LC treatments; their tumor
types and overall survival were similar to SEER LC par-
ticipants. However, HIV-LC patients were diagnosed
with LC at a younger age than their HIV-negative coun-
terparts. Future research should explore how screening
and diagnostic and treatment strategies directed toward
the general population may apply to HIV-positive
patients at risk for LC.
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